Pediatric Diabetes Management Market
Description
Pediatric Diabetes Market Summary
The global pediatric diabetes management market size was estimated at USD 5.59 billion in 2024 and is projected to reach USD 13.11 billion by 2033, growing at a CAGR of 9.96% from 2025 to 2033. The growth of the market is attributed to the rising global prevalence of diabetes, particularly Type 1, among children and adolescents, which has significantly increased the demand for effective monitoring and treatment solutions.
Technological advancements in blood glucose monitoring (BGM), continuous glucose monitoring (CGM), and insulin delivery systems have improved accuracy, convenience, and compliance, making them more suitable for pediatric use. Globally, type 1 diabetes remains the most common form in children, but the rising incidence of childhood obesity, sedentary lifestyles, and poor dietary habits has led to a significant rise in type 2 diabetes diagnoses in younger age groups. According to the International Diabetes Federation, around 1.52 million people aged 20 years had diabetes in 2022. This high prevalence of diabetes is increasing demand for constant monitoring and long-term disease management, thereby contributing to demand for pediatric-focused diabetes care solutions. The increasing regulatory support and initiatives to address diabetes in pediatric patient groups further fuel the market growth.
Technological advancements in diabetes management devices have significantly influenced the market growth as comfort, usability, and real-time insights are crucial for disease adherence. Companies are increasingly investing in the development of compact, minimally invasive, and user-friendly devices that cater specifically to children and adolescents. Innovations such as tubeless insulin pumps, continuous glucose monitors (CGMs) with extended sensor life, and smartphone-connected systems have improved patient compliance and parental monitoring. These devices reduce the burden on both children and caregivers by automating insulin dosing and generating predictive alerts, minimizing the risks of hypoglycemia or hyperglycemia.
Additionally, market players are focusing on launching pediatric-specific design features, such as miniaturization of products, further contributing to their increasing adoption. For instance, in July 2023, Tandem Diabetes Care’s miniature-sized insulin pump, Tandem Mobi, controllable via iPhone app and compatible with CGM, got FDA clearance for children (≥6 years) and adults. Half the size of t : slim X2, it integrates Control IQ automation, features shorter tubing, and remote updates.
Global Pediatric Diabetes Management Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global pediatric diabetes management market report on the basis of product, technology, end-use, and region:
The global pediatric diabetes management market size was estimated at USD 5.59 billion in 2024 and is projected to reach USD 13.11 billion by 2033, growing at a CAGR of 9.96% from 2025 to 2033. The growth of the market is attributed to the rising global prevalence of diabetes, particularly Type 1, among children and adolescents, which has significantly increased the demand for effective monitoring and treatment solutions.
Technological advancements in blood glucose monitoring (BGM), continuous glucose monitoring (CGM), and insulin delivery systems have improved accuracy, convenience, and compliance, making them more suitable for pediatric use. Globally, type 1 diabetes remains the most common form in children, but the rising incidence of childhood obesity, sedentary lifestyles, and poor dietary habits has led to a significant rise in type 2 diabetes diagnoses in younger age groups. According to the International Diabetes Federation, around 1.52 million people aged 20 years had diabetes in 2022. This high prevalence of diabetes is increasing demand for constant monitoring and long-term disease management, thereby contributing to demand for pediatric-focused diabetes care solutions. The increasing regulatory support and initiatives to address diabetes in pediatric patient groups further fuel the market growth.
Technological advancements in diabetes management devices have significantly influenced the market growth as comfort, usability, and real-time insights are crucial for disease adherence. Companies are increasingly investing in the development of compact, minimally invasive, and user-friendly devices that cater specifically to children and adolescents. Innovations such as tubeless insulin pumps, continuous glucose monitors (CGMs) with extended sensor life, and smartphone-connected systems have improved patient compliance and parental monitoring. These devices reduce the burden on both children and caregivers by automating insulin dosing and generating predictive alerts, minimizing the risks of hypoglycemia or hyperglycemia.
Additionally, market players are focusing on launching pediatric-specific design features, such as miniaturization of products, further contributing to their increasing adoption. For instance, in July 2023, Tandem Diabetes Care’s miniature-sized insulin pump, Tandem Mobi, controllable via iPhone app and compatible with CGM, got FDA clearance for children (≥6 years) and adults. Half the size of t : slim X2, it integrates Control IQ automation, features shorter tubing, and remote updates.
Global Pediatric Diabetes Management Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global pediatric diabetes management market report on the basis of product, technology, end-use, and region:
- Product Outlook (Revenue, USD Million, 2021 - 2033)
- Blood Glucose Monitors (BGM)
- Continuous Glucose Monitors (CGM)
- Insulin Pumps
- Insulin Pens
- Insulin Syringes
- Technology Outlook (Revenue, USD Million, 2021 - 2033)
- Connected Devices
- Non-connected Devices
- End Use Outlook (Revenue, USD Million, 2021 - 2033)
- Hospitals
- General Hospitals
- Children Hospitals
- Homecare
- Pediatric Clinics
- Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- Thailand
- South Korea
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- Kuwait
- UAE
Table of Contents
120 Pages
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Research Methodology
- 1.3. Information Procurement
- 1.4. Purchased database.
- 1.5. GVR’s internal database
- 1.6. Secondary sources
- 1.7. Third Party Perspective
- 1.8. Primary research
- 1.9. Details of primary research
- 1.10. Information or Data Analysis
- 1.11. Data analysis models
- 1.12. Market Formulation & Validation
- 1.13. Model Details
- 1.14. Commodity flow analysis (Model 1)
- 1.15. Approach 1: Commodity flow approach
- 1.16. Volume price analysis (Model 2)
- 1.17. Approach 2: Volume price analysis
- 1.18. List of Secondary Sources
- 1.19. List of Primary Sources
- 1.20. List of Abbreviations
- Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.3. Competitive Insights
- Chapter 3. Pediatric Diabetes Management Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Ancillary Market Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.1.1. Rising incidence of diabetes in children and adolescents
- 3.2.1.2. Technological advancements in diabetes management devices
- 3.2.1.3. Increasing awareness and early diagnosis
- 3.2.2. Market Restraint Analysis
- 3.2.2.1. High cost of certain diabetes management devices
- 3.2.3. Market Opportunities Analysis
- 3.2.3.1. Rising preference toward advanced diabetes management devices
- 3.2.4. Market Challenges Analysis
- 3.2.4.1. Caregiver burden and patient education challenges
- 3.3. Pediatric Diabetes Management Market Analysis Tools
- 3.3.1. Industry Analysis - Porter’s
- 3.3.1.1. Bargaining power of suppliers
- 3.3.1.2. Bargaining power of buyers
- 3.3.1.3. Threat of substitutes
- 3.3.1.4. Threat of new entrants
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political & Legal Landscape
- 3.3.2.2. Economic and Social Landscape
- 3.3.2.3. Technological landscape
- Chapter 4. Pediatric Diabetes Management Market: Product Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. Pediatric Diabetes Management Market: Product Movement Analysis & Market Share, 2024 & 2033
- 4.3. Blood Glucose Monitors (BGM)
- 4.3.1. Blood Glucose Monitors (BGM) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.4. Continuous Glucose Monitors (CGM)
- 4.4.1. Continuous Glucose Monitors (CGM) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.5. Insulin Pumps
- 4.5.1. Insulin Pumps Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.6. Insulin Pens
- 4.6.1. Insulin Pens Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.7. Insulin Syringes
- 4.7.1. Insulin Syringes Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- Chapter 5. Pediatric Diabetes Management Market: Technology Estimates & Trend Analysis
- 5.1. Segment Dashboard
- 5.2. Pediatric Diabetes Management Market: Technology Movement Analysis & Market Share, 2024 & 2033
- 5.3. Connected Devices
- 5.3.1. Connected Devices Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.4. Non-connected Devices
- 5.4.1. Non-connected Devices Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- Chapter 6. Pediatric Diabetes Management Market: End-use Estimates & Trend Analysis
- 6.1. Segment Dashboard
- 6.2. Pediatric Diabetes Management Market: End-use Movement Analysis & Market Share, 2024 & 2033
- 6.3. Hospitals
- 6.3.1. Hospitals Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.3.2. General Hospitals
- 6.3.2.1. General Hospitals Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.3.3. Children Hospitals
- 6.3.3.1. Children Hospitals Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.4. Homecare
- 6.4.1. Homecare Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.5. Pediatric Clinics
- 6.5.1. Pediatric Clinics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- Chapter 7. Pediatric Diabetes Management Market: Regional Estimates & Trend Analysis by Product, Technology, End-Use
- 7.1. Regional Outlook
- 7.2. Pediatric Diabetes Management Market: Regional Movement Analysis & Market Share, 2024 & 2033
- 7.3. North America
- 7.3.1. North America Pediatric Diabetes Management Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.3.2. U.S.
- 7.3.2.1. Key Country Dynamics
- 7.3.2.2. Competitive Scenario
- 7.3.2.3. Regulatory Scenario
- 7.3.2.4. Reimbursement Scenario
- 7.3.2.5. U.S. Pediatric Diabetes Management Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.3.3. Canada
- 7.3.3.1. Key Country Dynamics
- 7.3.3.2. Competitive Scenario
- 7.3.3.3. Regulatory Scenario
- 7.3.3.4. Reimbursement Scenario
- 7.3.3.5. Canada Pediatric Diabetes Management Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.3.4. Mexico
- 7.3.4.1. Key Country Dynamics
- 7.3.4.2. Competitive Scenario
- 7.3.4.3. Regulatory Scenario
- 7.3.4.4. Reimbursement Scenario
- 7.3.4.5. Mexico Pediatric Diabetes Management Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4. Europe
- 7.4.1. Europe Pediatric Diabetes Management Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.2. UK
- 7.4.2.1. Key Country Dynamics
- 7.4.2.2. Competitive Scenario
- 7.4.2.3. Regulatory Scenario
- 7.4.2.4. Reimbursement Scenario
- 7.4.2.5. UK Pediatric Diabetes Management Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.3. Germany
- 7.4.3.1. Key Country Dynamics
- 7.4.3.2. Competitive Scenario
- 7.4.3.3. Regulatory Scenario
- 7.4.3.4. Reimbursement Scenario
- 7.4.3.5. Germany Pediatric Diabetes Management Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.4. France
- 7.4.4.1. Key Country Dynamics
- 7.4.4.2. Competitive Scenario
- 7.4.4.3. Regulatory Scenario
- 7.4.4.4. Reimbursement Scenario
- 7.4.4.5. France Pediatric Diabetes Management Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.5. Italy
- 7.4.5.1. Key Country Dynamics
- 7.4.5.2. Competitive Scenario
- 7.4.5.3. Regulatory Scenario
- 7.4.5.4. Reimbursement Scenario
- 7.4.5.5. Italy Pediatric Diabetes Management Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.6. Spain
- 7.4.6.1. Key Country Dynamics
- 7.4.6.2. Competitive Scenario
- 7.4.6.3. Regulatory Scenario
- 7.4.6.4. Reimbursement Scenario
- 7.4.6.5. Spain Pediatric Diabetes Management Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.7. Denmark
- 7.4.7.1. Key Country Dynamics
- 7.4.7.2. Competitive Scenario
- 7.4.7.3. Regulatory Scenario
- 7.4.7.4. Reimbursement Scenario
- 7.4.7.5. Denmark Pediatric Diabetes Management Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.8. Sweden
- 7.4.8.1. Key Country Dynamics
- 7.4.8.2. Competitive Scenario
- 7.4.8.3. Regulatory Scenario
- 7.4.8.4. Reimbursement Scenario
- 7.4.8.5. Sweden Pediatric Diabetes Management Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.9. Norway
- 7.4.9.1. Key Country Dynamics
- 7.4.9.2. Competitive Scenario
- 7.4.9.3. Regulatory Scenario
- 7.4.9.4. Reimbursement Scenario
- 7.4.9.5. Norway Pediatric Diabetes Management Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5. Asia Pacific
- 7.5.1. Asia Pacific Pediatric Diabetes Management Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.2. Japan
- 7.5.2.1. Key Country Dynamics
- 7.5.2.2. Competitive Scenario
- 7.5.2.3. Regulatory Scenario
- 7.5.2.4. Reimbursement Scenario
- 7.5.2.5. Japan Pediatric Diabetes Management Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.3. China
- 7.5.3.1. Key Country Dynamics
- 7.5.3.2. Competitive Scenario
- 7.5.3.3. Regulatory Scenario
- 7.5.3.4. Reimbursement Scenario
- 7.5.3.5. China Pediatric Diabetes Management Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.4. India
- 7.5.4.1. Key Country Dynamics
- 7.5.4.2. Competitive Scenario
- 7.5.4.3. Regulatory Scenario
- 7.5.4.4. Reimbursement Scenario
- 7.5.4.5. India Pediatric Diabetes Management Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.5. South Korea
- 7.5.5.1. Key Country Dynamics
- 7.5.5.2. Competitive Scenario
- 7.5.5.3. Regulatory Scenario
- 7.5.5.4. Reimbursement Scenario
- 7.5.5.5. South Korea Pediatric Diabetes Management Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.6. Australia
- 7.5.6.1. Key Country Dynamics
- 7.5.6.2. Competitive Scenario
- 7.5.6.3. Regulatory Scenario
- 7.5.6.4. Reimbursement Scenario
- 7.5.6.5. Australia Pediatric Diabetes Management Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.7. Thailand
- 7.5.7.1. Key Country Dynamics
- 7.5.7.2. Competitive Scenario
- 7.5.7.3. Regulatory Scenario
- 7.5.7.4. Reimbursement Scenario
- 7.5.7.5. Thailand Pediatric Diabetes Management Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6. Latin America
- 7.6.1. Latin America Pediatric Diabetes Management Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.2. Brazil
- 7.6.2.1. Key Country Dynamics
- 7.6.2.2. Competitive Scenario
- 7.6.2.3. Regulatory Scenario
- 7.6.2.4. Reimbursement Scenario
- 7.6.2.5. Brazil Pediatric Diabetes Management Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.3. Argentina
- 7.6.3.1. Key Country Dynamics
- 7.6.3.2. Competitive Scenario
- 7.6.3.3. Regulatory Scenario
- 7.6.3.4. Reimbursement Scenario
- 7.6.3.5. Argentina Pediatric Diabetes Management Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7. Middle East & Africa
- 7.7.1. Middle East & Africa Pediatric Diabetes Management Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7.2. South Africa
- 7.7.2.1. Key Country Dynamics
- 7.7.2.2. Competitive Scenario
- 7.7.2.3. Regulatory Scenario
- 7.7.2.4. Reimbursement Scenario
- 7.7.2.5. South Africa Pediatric Diabetes Management Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7.3. Saudi Arabia
- 7.7.3.1. Key Country Dynamics
- 7.7.3.2. Competitive Scenario
- 7.7.3.3. Regulatory Scenario
- 7.7.3.4. Reimbursement Scenario
- 7.7.3.5. Saudi Arabia Pediatric Diabetes Management Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7.4. UAE
- 7.7.4.1. Key Country Dynamics
- 7.7.4.2. Competitive Scenario
- 7.7.4.3. Regulatory Scenario
- 7.7.4.4. Reimbursement Scenario
- 7.7.4.5. UAE Pediatric Diabetes Management Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7.5. Kuwait
- 7.7.5.1. Key Country Dynamics
- 7.7.5.2. Competitive Scenario
- 7.7.5.3. Regulatory Scenario
- 7.7.5.4. Reimbursement Scenario
- 7.7.5.5. Kuwait Pediatric Diabetes Management Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- Chapter 8. Competitive Landscape
- 8.1. Market Participant Categorization
- 8.2. Key Company Profiles
- 8.2.1. Medtronic
- 8.2.1.1. Company Overview
- 8.2.1.2. Financial Performance
- 8.2.1.3. Product Benchmarking
- 8.2.1.4. Strategic Initiatives
- 8.2.2. Dexcom
- 8.2.2.1. Company Overview
- 8.2.2.2. Financial Performance
- 8.2.2.3. Product Benchmarking
- 8.2.2.4. Strategic Initiatives
- 8.2.3. Abbott
- 8.2.3.1. Company Overview
- 8.2.3.2. Financial Performance
- 8.2.3.3. Product Benchmarking
- 8.2.3.4. Strategic Initiatives
- 8.2.4. Tandem Diabetes Care
- 8.2.4.1. Company Overview
- 8.2.4.2. Financial Performance
- 8.2.4.3. Product Benchmarking
- 8.2.4.4. Strategic Initiatives
- 8.2.5. Insulet Corporation
- 8.2.5.1. Company Overview
- 8.2.5.2. Financial Performance
- 8.2.5.3. Product Benchmarking
- 8.2.5.4. Strategic Initiatives
- 8.2.6. Novo Nordisk
- 8.2.6.1. Company Overview
- 8.2.6.2. Financial Performance
- 8.2.6.3. Product Benchmarking
- 8.2.6.4. Strategic Initiatives
- 8.2.7. Sanofi
- 8.2.7.1. Company Overview
- 8.2.7.2. Financial Performance
- 8.2.7.3. Product Benchmarking
- 8.2.7.4. Strategic Initiatives
- 8.2.8. Eli Lilly and Company
- 8.2.8.1. Company Overview
- 8.2.8.2. Financial Performance
- 8.2.8.3. Product Benchmarking
- 8.2.8.4. Strategic Initiatives
- 8.2.9. Roche Diabetes Care
- 8.2.9.1. Company Overview
- 8.2.9.2. Financial Performance
- 8.2.9.3. Product Benchmarking
- 8.2.9.4. Strategic Initiatives
- 8.2.10. Ascensia Diabetes Care
- 8.2.10.1. Company Overview
- 8.2.10.2. Financial Performance
- 8.2.10.3. Product Benchmarking
- 8.2.10.4. Strategic Initiatives
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
